EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Predictive value of D4Z4 methylation levels for phenotypic heterogeneity and disease progression in Facioscapulohumeral Muscular Dystrophy with borderline D4Z4 repeat units: a retrospective cohort study

Xiaodan Lin, Qifang He, Minghui Zeng, Yuhua Lin, Xinrong Xu, Xinyue Chen, Xin Lin, Zhiqiang Wang

PeerJ · 02.04.2026 · 14 · e21043

DOI: 10.7717/peerj.21043 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PeerJ, online erschienen am 02.04.2026. Verfasst von Xiaodan Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Institute of Neurology of the First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecula…. Hauptthemen laut MEDLINE: DNA Methylation, Muscular Dystrophy, Facioscapulohumeral. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Facioscapulohumeral muscular dystrophy (FSHD) patients carrying borderline D4Z4 repeat units (DRUs) (8–10) represent a molecularly ambiguous group overlapping FSHD1 and FSHD2, characterized by pronounced phenotypic heterogeneity. This study aimed to determine the association between methylation levels and disease severity, progression in this undercharacterized cohort.

Methods

This single-center and retrospective cohort study (ClinicalTrials.gov: NCT04369209), was conducted at the Fujian Neuromedical Centre (FNMC), China. Methylation levels were quantified using bisulfite sequencing in all participants. Whole-exome sequencing (WES) was performed for all probands. Phenotypic classification followed the Comprehensive Clinical Evaluation Form (CCEF). Motor function was assessed using the FSHD clinical score, clinical severity scale (CSS), and age-corrected CSS. Key functional endpoints were defined as follows: (1) lower extremity involvement, CSS ≥ 3.0; and (2) independent ambulation loss, CSS 4.5–5.

Results

The patients carrying borderline DRUs exhibited milder phenotypes, broader phenotypic variability and lower methylation levels compared to those carrying 4–7 DRUs. The mean methylation levels of the 10 CpG sites and CpG6 methylation levels showed significant negative correlations with FSHD clinical score, CSS, and age-corrected CSS. Those methylation thresholds effectively discriminated symptomatic from asymptomatic patients with borderline DRUs. Furthermore, patients with lower methylation levels exhibited higher disease penetrance and an increased risk of progressing to lower extremity involvement. In a multigenerational pedigree, cooccurrence of a pathogenic SMCHD1 variant exacerbated hypomethylation and clinical severity.

Conclusions

Hypomethylation of the distal D4Z4 array serves as a robust biomarker for phenotypic penetrance and disease progression in borderline-allele FSHD. The co-presence of mutations in epigenetic modulators ( e.g. , SMCHD1 ) and D4Z4 hypomethylation is correlated with more severe clinical phenotypes, underscoring a compound epigenetic-genetic disease mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationMuscular Dystrophy, FacioscapulohumeralAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDisease ProgressionExome SequencingPedigreePhenotypeRetrospective StudiesSeverity of Illness IndexChromosomal Proteins, Non-Histone

Stichwörter der Autor:innen

Borderline D4Z4 repeat unitsDNA methylationDisease progressionFacioscapulohumeral muscular dystrophyPhenotypic heterogeneitySMCHD1 mutation

Substanzen

SMCHD1 protein, humanChromosomal Proteins, Non-Histone

Autor:innen und Institutionen

  • Department of Neurology and Institute of Neurology of the First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, Fujian, China.
  • Department of Neurology, Affiliated Mindong Hospital, Fujian Medical University, Fuan, Fujian, China.
  • Department of Neurology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, China.

Förderung

  • Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Lin, X., He, Q., Zeng, M., Lin, Y., Xu, X., Chen, X., Lin, X., & Wang, Z. (2026). Predictive value of D4Z4 methylation levels for phenotypic heterogeneity and disease progression in Facioscapulohumeral Muscular Dystrophy with borderline D4Z4 repeat units: a retrospective cohort study. PeerJ, 14, e21043. https://doi.org/10.7717/peerj.21043

Vancouver

Lin X, He Q, Zeng M, Lin Y, Xu X, Chen X, et al. Predictive value of D4Z4 methylation levels for phenotypic heterogeneity and disease progression in Facioscapulohumeral Muscular Dystrophy with borderline D4Z4 repeat units: a retrospective cohort study. PeerJ. 2026;14:e21043. doi:10.7717/peerj.21043

BibTeX
@article{Lin2026,
  author = {Lin, Xiaodan and He, Qifang and Zeng, Minghui and Lin, Yuhua and Xu, Xinrong and Chen, Xinyue and Lin, Xin and Wang, Zhiqiang},
  title = {Predictive value of D4Z4 methylation levels for phenotypic heterogeneity and disease progression in Facioscapulohumeral Muscular Dystrophy with borderline D4Z4 repeat units: a retrospective cohort study},
  journal = {PeerJ},
  year = {2026},
  volume = {14},
  pages = {e21043},
  doi = {10.7717/peerj.21043}
}
Kostenlos starten →